- Home
- NVS
NVS
Novartis AG
as 07-26-2024 4:00pm EST
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 214.9B | IPO Year: | 1991 |
| Target Price: | $117.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 7.86 | EPS Growth: | 118.94 |
| 52 Week Low/High: | $92.19 - $112.48 | Next Earning Date: | 07-18-2024 |
| Revenue: | $48,860,000,000 | Revenue Growth: | 9.70% |
| Revenue Growth (this year): | 7.49% | Revenue Growth (next year): | 4.29% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
2 days ago
Dren Bio and Novartis link on bispecific antibodies for cancer
Zacks
2 days ago
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
BioPharma Dive
3 days ago
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
MT Newswires
4 days ago
DA Davidson Raises Price Target on Novartis to $120 From $110, Maintains Buy/Add Rating
Zacks
4 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Argus Research
7 days ago
Analyst Report: Novartis AG
Argus Research
7 days ago
Market Update: NVS, AXP, DPZ, EFX, MTB, CRWD
Zacks
7 days ago
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.